



Relation of Genetic Polymorphism of ABCG2 Gene and Occurrence of Oxaliplatin- Induced Peripheral Neuropathy in Patients with Gastrointestinal Tract Cancer

A Thesis Submitted for Fulfillment of Master Degree in
Pharmaceutical Sciences (Clinical Pharmacy)

By

Inas Moawya Moukhtar Ahmed, Bsc

Bachelor of Pharmaceutical Sciences

Modern Science and Arts University (MSA) (2010)

Under Supervision of

Dr. Lamia Mohamed El Wakeel, PhD

Assistant Professor of Clinical Pharmacy

Faculty of Pharmacy

Ain Shams University

Dr. Abdel Hady Aly Abdel Wahab, PhD

Professor of Biochemistry

and Molecular Biology

Cancer Biology Department

National Cancer Institute

Cairo University

Dr. Amr Shafik Tawfik, MD, PhD

Assistant Professor of Clinical Oncology

Faculty of Medicine

Ain Shams University

Faculty of Pharmacy

Ain Shams University

2019

Acknowledgments

First and foremost, I am and will always be indebted to Allah, the most gracious and merciful.

I would like to express my deep appreciation and sincere gratitude to **Dr. Abdel Hady Aly Abdel Wahab**, Professor of Biochemistry and Molecular Biology at Cancer Biology Department, National Cancer Institute, Cairo University for his continuous support and help. I am so grateful for his generous support, endless help throughout the work and for granting me the honor to join his team and laboratory, supplying me with the required materials, sharing his knowledge and helping me all through the study phases. His guidance and mentorship helped me all the way to completion of this degree. It was a great honor for me to work under his supervision.

I am greatly honored to express my deep gratitude and appreciation to **Dr. Amr Shafik Tawfik Saad**, Assistant Professor of Clinical Oncology, Faculty of Medicine, Ain Shams University for his fruitful supervision, helpful guidance, continuous motivation and encouragement through the various stages of this study.

Words stand short to express my sincere gratitude and faithfulness to **Dr. Lamia Mohamed El Wakeel**, Assistant Professor of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University for her strict supervision and revision of this work. Her valuable comments, effort and collaboration were the causes to complete this work properly.

I am deeply indebted to **Dr. Raafat Ragaie Abdel-Malek**, Assistant Professor of Clinical Oncology, Faculty of Medicine, Cairo University for his sincere and endless help throughout this work, his valuable comments were of great value for completion of this work. It was a great honor to work with his sincere guidance.

My appreciation and deep thanks to ***Dr. Ahmed Atef Emam***, Department of Cancer Biology, National Cancer Institute, Cairo University, for his sincere help in every step of genetic testing.

My appreciation and deep thanks to ***Dr. Eman Gamal Ayad***, Lecturer of biochemistry Department of chemistry, Faculty of science, Helwan University, for her sincere help and support to complete this work.

Gratitude and indebtedness also extend to the staff members of the Clinical Oncology Department, Ain Shams University and members of Cancer Biology Department in National Cancer Institute for their great help and by whom all, I was very much impressed by the noble characters and generous attitude.

Last but certainly not least, I would like to thank all my colleagues in the Department of Clinical Pharmacy, Nurses and all patients who participated in this study and everyone who made any effort for this work to become a reality.

Finally, I would like to express my deep gratitude and thanks to my family: my parents, sisters, brother and my friends for giving me all wholehearted support to continue, great help and continuous encouragement.

Contents

List of Tables	i
List of Figures	ii
List of Abbreviations	iii
Abstract	v
Introduction	1
Review of literature	4
1. Gastrointestinal cancers	4
2. Peripheral Neuropathy.....	11
3. Oxaliplatin	15
4. Type of neurotoxicity associated with oxaliplatin.....	20
5. Mechanisms of oxaliplatin induce peripheral neuropathy.....	21
6. Risk Factors of oxaliplatin induced peripheral neuropathy.....	23
7. Assessment of oxaliplatin induced peripheral neuropathy.....	24
8. Management of oxaliplatin Induced Peripheral Neuropathy.....	28
9. Pharmacogenetics.....	33
10. ABCG2 gene.....	34
11. The Role of the Clinical Pharmacist.....	37
Aim of The Work	41
Patients and Methods	42
Results	67
Discussion	95
Conclusion and Recommendation	101
Summary	103
References	107

Appendices	135
Appendix 1: Patients Demographics and Baseline Data	136
Appendix 2: Genotyping Analysis of ABCG2 G34A SNP at rs2231137 locus...	140
Appendix 3: Genotyping Analysis of ABCG2 SNPs at rs3114018 locus.....	142
Appendix 4: Sensory Peripheral Neuropathy Assessment According to National Cancer Institute Common Toxicity Criteria version 4...	144
Appendix 5: Motor Peripheral Neuropathy Assessment According to National Cancer Institute Common Toxicity Criteria version 4.....	146
Appendix 6: Laboratory Data of GIT Cancer Patients Before and After Oxaliplatin	148
Appendix 7: Samples Represent Sequencing Analysis for ABCG2 polymorphism at rs2231137 locus	152
Appendix 8: Samples Represent Sequencing Analysis for ABCG2 polymorphism at rs3114018 locus.....	156
Appendix 9: Consent Form.....	164
Appendix 10: Research ethics approval protocol	166
Arabic Summary.....	1

List of Tables

Table	Page
Table1.1: Antineoplastic agents that cause CIPN	12
Table 1.2: Pharmacokinetics of oxaliplatin	17
Table 1.3: Grading scales for CIPN	25
Table 1.4: Grading of oxaliplatin-induced neurotoxicity	26
Table 1.5: Oxaliplatin neurotoxicity dose modifications	29
Table 2.1: Adverse Events Definition and Grading according to CTCAE v4. 2010	45
Table 2.2: Pairs of primers used for HRM screening and sequencing of ABCG2 gene	50
Table 2.3: Annealing and product size of primers used	54
Table 2.4: Polymerase chain reaction Conditions	54
Table 2.5: High resolution melting conditions used for analysis	58
Table 2.6: Reaction mix for quantitative polymerase chain reaction	60
Table 2.7: Conditions of quantitative polymerase chain reaction	61
Table 2.8: Reaction mix for Cycle Sequencing	63
Table 2.9: Condition of cycle sequencing	63
Table 3.1: Patients' Demographics and Baseline Data	70
Table 3.2: Laboratory data Before and After Oxaliplatin Treatment for GIT Cancer	73
Table 3.3: Relation of peripheral neuropathy frequency with patient's characteristics	74
Table 3.4: Association between the grade of sensory peripheral neuropathy and Patients characteristics	76
Table 3.5: Association between the grade of motor peripheral neuropathy and patient characteristics	78
Table3.6: Identification and classification of ABCG2 polymorphism at rs3114018 Locus	81
Table 3.7: Association between the frequency of SNPs of ABCG2 at rs3114018 locus and patients' characteristics	85
Table 3.8: The occurrence of peripheral neuropathy in relation to the different variants of ABCG2 at rs3114018 locus	86
Table 3.9: Association between the grades of sensory and motor neuropathy with the Variants of ABCG2 at rs3114018 locus	86
Table 3.10: Identification and classification of ABCG2 polymorphism at rs2231137 locus	88
Table 3.11: Association between frequency of ABCG2 Polymorphism at rs2231137 locus with patients' characteristics	91
Table 3.12: Association between the occurrence of peripheral neuropathy and the different variants of ABCG2 Polymorphism at rs2231137 locus	92
Table 3.13: Association between the grades of sensory and motor neuropathy and the Different Variants of ABCG2 Polymorphism at rs2231137 locus	93

List of Figures

Figure	Page
Figure 1.1: Oxaliplatin structure	15
Figure 1.2: Mechanism of oxaliplatin induces peripheral neuropathy	22
Figure 2.1: Self-reporting adverse event card	47
Figure 2.2: Nano-drop spectrophotometry	51
Figure 2.3: Gel electrophoresis apparatus	52
Figure 2.4: Thermal cycler	54
Figure 2.5: Melt curve for High Resolution Melting Technique	56
Figure 2.6: ViiA 7 for HRM	57
Figure 2.7: 3500 Genetic Analyzer	64
Figure 3.1: Study Flow Chart	67
Figure 3.2: patients demographics and baseline data	68
Figure 3.3: Metastasis at presentation in the GIT cancer patients	69
Figure 3.4.a: level of white Blood Cells Before and After Treatment	71
Figure 3.4.b: Level of Platelet Count Before and After Treatment	72
Figure 3.4.c: Level of Hemoglobin Before and After Treatment	72
Figure 3.5: Association of Peripheral neuropathy with different tumor grades in GIT cancer patients	75
Figure 3.6: Frequency of sensory peripheral neuropathy grades within the GIT cancer patients	76
Figure 3.7: Frequency of motor peripheral neuropathy grades within the GIT cancer patients	77
Figure 3.8: HRM Derivative melt curves for ABCG2 gene at rs3114018 locus for study population	80
Figure 3.9: HRM aligned melt curves for ABCG2 gene at rs3114018 locus for study population	80
Figure 3.10: Sequencing analysis for ABCG2 at rs3114018 locus represent variant 1 C/C allele	81
Figure 3.11: Sequencing analysis for ABCG2 at rs3114018 locus represent variant 2 A/C-A/C allele	82
Figure 3.12: Sequencing analysis for ABCG2 at rs3114018 locus represent variant 3 A/A allele wildtype.	82
Figure 3.13: Frequency of ABCG2 alleles at rs3114018 locus in the study populations	83
Figure 3.14: HRM Aligned Melt Curves for ABCG2 G34A Genotype at rs2231137 locus in the study population	87
Figure 3.15: HRM Derivative Melt Curves for ABCG2 G34 Genotype at rs2231137 locus for the study population	88
Figure 3.16: Sequencing analysis for ABCG2 at rs2231137 locus representing variant 1 G/A-G/A allele	89
Figure 3.17: Sequencing analysis for ABCG2 at rs2231137 locus representing variant 2 G/G allele wildtype	89
Figure 3.18: Frequency of ABCG2 G34A Alleles at rs2231137 Locus in the study population	90
Figure 3.19: The association between Peripheral neuropathy and ABCG2 G34A at rs2231137 locus in the study population	92

List of Abbreviations

	Full Term
5-FU	F – Fluorouracil
A	Absorbance
ABC	ATP-binding cassette transporters on plasma membranes
ABCG2	ATP-binding cassette, subfamily G, isoform 2 protein
ADL	Activities of daily living
AEs	Adverse events
ALT	Alanine transaminase enzyme
ART	Antiretroviral therapy
AST	Aspartate transaminase enzyme
ATP	Adenosine Triphosphate
BBB	Blood brain barrier
Bp	Base pair
CA 19.9	Carbohydrate tumor-associated antigen
CIPN	Chemotherapy-induced peripheral neuropathy
CI	Confidence interval
CMT	Charcot-Marie-Tooth disease
CNS	Central nervous system
CRC	Colorectal cancer
CTCAE	Common terminology criteria for adverse events
D5W	Dextrose and water
DACH	Diaminocyclohexane
DNA	Deoxyribose nucleic acid
DRG	dorsal root ganglion
DsDNA	Double-strand DNA
EC	Esophageal cancer
ECOG	Eastern Cooperative Oncology Group
FDA	Food and drug administration
FOLOFX	FOL–Folinic acid (leucovorin), F – Fluorouracil (5-FU), and OX– Oxaliplatin.
g DNA	Genomic DNA
GBC	Gallbladder carcinoma
GC	Gastric carcinoma
gDNA	Genomic DNA
GI	Gastrointestinal
GIT	Gastrointestinal tract
GST	Glutathione S-transferases
H2O	Dihydrogen Monoxide (water)
HCC	Hepatocellular carcinoma
HIV	Human immunodeficiency virus disease
HRM	High resolution melting technique
IBS	Irritable bowel syndrome

List of Abbreviations

	Full Term
IENF	Intraepidermal nerve fiber
IGF1	Insulin-like Growth Factor-1
LDI	Laser Doppler imager technique
MDR	Multidrug resistance
NCI	National cancer institute
NCI-CTC	National cancer institute of health-common terminology criteria
NSAIDs	Non-steroidal anti-inflammatory drugs
NTC	No template control
OR	Odds ratio
OIPN	Oxaliplatin induced peripheral neuropathy
OIIT	Oxaliplatin-induced immune thrombocytopenia
PAC	Pancreatic adenocarcinoma
PBS	Phosphate Buffered Saline
PCR	Polymerase Chain Reaction
PN	Peripheral neuropathy
PNS	Peripheral nervous system
PNQ	Patient Neurotoxicity Questionnaire
PV	Pain Vision Device
QOL	Quality of life
QPCR	Quantitative polymerase chain reaction
QST	Quantitative sensory testing
RT	Room temperature
SNPs	Single nucleotide polymorphisms
TBE	Tris/Borate/EDTA
Tm	Melting temperature
TNS	Total neuropathy score
US	United State
UV	Ultraviolet-visible
WHO	World health organization

Abstract

Background: Oxaliplatin use in gastrointestinal malignancies is limited by neurotoxicity. The aim of the current study was to identify single-nucleotide polymorphisms (SNPs) in ABCG2 gene involved in oxaliplatin-induced peripheral neuropathy (OIPN) among Egyptian Colorectal Cancer (CRC) patients treated with oxaliplatin-based chemotherapy (CT) together with its association with other patient characteristics.

Patients and methods: All eligible Colorectal Cancer patients were included in the study if they were between 18-80 years old and excluded if they had a neurologic disease or a disease impairing neurologic function. OIPN was evaluated and graded on day 1 of each CT cycle according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v.4). The Genomic DNA was extracted from blood to detect SNPs within the ABCG2 gene (at rs2231137 and at rs3114018) using High Resolution Melting (**HRM**) technique followed by direct sequencing method for every melting cluster using 3500 genetic analyzer for the samples selected from each cluster.

Results: The occurrence of grade 2-3 OIPN was higher in patients carrying the G/G genotype of ABCG2 (rs2231137) than those with G/A genotype at the same locus (rs2231137) (96.7% versus 82.0%; $p=0.05$). While, grade 2-3 OIPN occurrence was not significantly different in patients carrying genotypes (C/C, AC/AC and A/A) of ABCG2 at rs3114018 (92.9%, 82.1% and 80.0% respectively; $p=0.309$).

From a total of 47 females and 33 males; 41(87.2%) females and 29 (87.9%) males suffered from different grades of sensory and motor peripheral neuropathy. Regarding sensory oxaliplatin-induced peripheral neuropathy (OIPN), females had higher risk of grade II-III PN than males (92.7% versus 58.6% respectively; $p=0.001$) For motor OIPN, females were more susceptible to grade II-III PN versus males (84.6% versus 56.5% respectively; $p=0.015$).

Conclusion: The occurrence of OIPN among Egyptian Colorectal Cancer (CRC) patients was more associated with the G/G allele genotype of ABCG2 (rs2231137). While patients carrying different genotypes (C/C, AC/AC and

A/A) of ABCG2 at rs3114018 were similarly associated with OIPN in this patient population. The high grade (grade II-III) Oxaliplatin-induced sensory and motor peripheral neuropathy occurred more frequently in females versus males Egyptian colorectal cancer patients.

Keywords: Oxaliplatin-Induced Peripheral Neuropathy, ABCG2, Colorectal Cancer, High Resolution Melting Technique, 3500 Genetic Analyzer, females, males.

Introduction

Gastrointestinal tract (GIT) cancer, especially colorectal , gastric and pancreatic cancers are a global epidemiological health concern (**Lambert R and Hainaut P 2007**). There were estimated 1,500,000 new cases of GIT cancer worldwide in 2005 and the number is expected to rise to 2,110,000 in 2025 (**Jemal A, Bray F et al., 2011**). Gastric and colon cancers were the second and third most common causes of cancer-related mortality worldwide in 2008, respectively, accounting for over 1 million deaths (**Ferlay J, Shin HR et al., 2010**).

Generally, GIT cancer is known to be a multifactorial disease induced by complex interactions between environmental and genetic factors (**Pharoah PD, Dunning AM et al., 2004**). Previous studies suggest that lifestyle, dietary, genetic factors and other environmental exposures, might have played a role in causing GIT cancer (**McCormack VA and Boffetta P 2011**). However, the majority of genetic variants that influence susceptibility to GIT cancer are not well-known (**Lichtenstein P, Holm NV et al., 2000**). Genetic factors may be important contributors to the risk of GIT cancer, efficacy and adverse events (AEs) severity of chemotherapy (**Lochhead P, Frank B et al., 2011; Ye F, Liu Z et al., 2013; Custodio A, Moreno-Rubio J et al., 2014**).

The World Cancer Research Fund estimated that half of the cases may be prevented by dietary and other lifestyle changes (<http://www.wcrf.org/>). Early detection leading to early treatment will save lives (<http://www.ueg.eu/press/crceurope/>) Therefore, strategies for prevention, early detection and treatment modalities are highly ensured. The various treatments plan of GIT cancer include surgery, chemotherapy and/or radiation therapy vary depending on the size, location, extent of tumor and the patient's overall health (**Earle CC, Maroun J et al., (2002)**).

As mentioned, Chemotherapy is routinely used alone or in combination with other therapies to treat patients following cancer diagnosis. However, chemotherapy-induced peripheral neuropathy (CIPN) is a type of neuropathic pain that is a major disabling side effect of several commonly used chemotherapeutic agents. Its

development may require chemotherapy dose reduction or cessation, which may increase cancer-related morbidity and mortality (**Gutiérrez-Gutiérrez G, Sereno M, et al., 2010**).

Chemotherapy-induced peripheral neuropathy is a predominantly sensory neuropathy but it may also occur as a motor dysfunction and occasionally it can be accompanied by dysfunction of the autonomic nervous system. (**Boland BA, Sherry V et al., 2010**)

Incidence rates of CIPN available in the literature are highly variable, ranging from 10 to 100%. The influencing factors include: type of antineoplastic agent, treatment schedule being administered (dose, number of cycles, ...), combinations of different neurotoxic agents, patient characteristics (age, pre-existing causes of peripheral neuropathy as diabetes mellitus, Renal or hepatic dysfunction, vitamin B12 deficiency), and the diagnostic scale of assessment of the CIPN (**Balayssac D, Ferrier J, et al., 2011**).

Chemotherapy induced peripheral neuropathy CIPN is typically seen in about 40% (**Windebank AJ and Grisold W 2008; Paice JA 2011; Vincenzi B, Frezza AM et al., 2013**) of patients treated with platinum based treatments, including Oxaliplatin. It is assumed that platinum compounds, which bind irreversibly to the DNA, induce apoptosis of sensory neurons (**Von Schlippe M, Fowler CJ et al., 2001**). The persistent cumulative injury caused by antineoplastic agents mostly affect sensory nerve cell bodies in the Dorsal root ganglia and/or the afferent and efferent axons of the peripheral nervous system (**Quasthoff and Hartung, 2002; Windebank AJ and Grisold W 2008**). These typically lead to severe neurotoxicity which results in sensory and motor neurodegeneration, and is classified as pain associated with touch, ‘pins and needles’ and numbness as well as loss of motor coordination (**Paice JA 2011**). These symmetrical sensory complications are routinely identified in the extremities e.g. fingers and toes, with symptoms persisting from weeks/months to many years. Moreover, the symptoms of CIPN may remain after discontinuation of treatment with platinum compounds (**van den Bent MJ 2005; Pietrangeli A, Leandri M et al., 2006; Windebank AJ and W Grisold 2008; Vincenzi B, Frezza AM et al., 2013**). Clinical studies suggest that genomic findings can translate into

improvements in clinical practice (**Evans WE and McLeod HL 2003; Rieder MJ, Reiner AP et al., 2005**).

A previous study suggested an association between genetic variants of ABCG2 gene and severe peripheral neuropathy adverse events end points of oxaliplatin chemotherapy (**Custodio A, Moreno-Rubio J et al., 2014**).

The diagnosis of CIPN is mainly clinical, detailed history and physical examination are the most important methods for early detection. Several toxicity grading scales have been developed to assess the severity of peripheral neurotoxicity. The grading is based on symptoms and functional capacity reported by the patient and findings in physical examination. The most commonly used scale is NCI-CTCAE (Common Terminology Criteria for Adverse Events). Other grading scales used in clinical practice are the World health organization (WHO), Eastern Cooperative Oncology Group (ECOG) scales and the oxaliplatin grading scale of Levi, Patient Neurotoxicity Questionnaire (PNQ) and The Total Neuropathy Score (TNS) (**Griffith KA, Zhu S et al., 2017**).

As anticancer therapy is often associated with severe adverse events (AEs), there is an increasing demand for effective supportive care strategies preventing or ameliorating drug-induced toxicity. The addition of a pharmacist to the health care team may ensure appropriate medication use, maximize adherence, minimizing treatment-related toxicity; therefore, focus on optimizing supportive care strategies (**Liekweg A, Westfeld M et al. 2012**). The concordance and communication between patients and pharmacists may improve patients' understanding of pharmacotherapy. Pharmacist intervention has been shown to result in improved patient care. Pharmacist counseling cannot change the physical AEs of adjuvant systemic therapy but may be able to prevent deterioration of Quality of life (QOL) by emotionally preparing the patient to tolerate the AEs (**Kawaguchi T, Iwase S et al., 2012**).

1. Gastrointestinal Cancers

1.1. Epidemiology and Types:

Cancers of the digestive system can be mainly divided into esophageal cancer (EC), gastric carcinoma (GC), colorectal cancer (CRC), a gallbladder carcinoma (GBC), hepatocellular carcinoma (HCC) and pancreatic adenocarcinoma (PAC). According to the global cancer statistics in 2012, HCC was identified as the second most frequently diagnosed cancers among men in less developed countries. Esophageal cancer EC, had highest rates in East Asia, and caused 400,200 deaths worldwide in 2012. While there were around 1.4 million cases of CRC patients and 693,900 deaths that occurred due to CRC (**Torre LA, Bray F et al., 2015**).

Colorectal cancer (CRC) is the third most commonly diagnosed cancer and a major cause of cancer related mortality. CRC is a multistep process in which a combination of genetic and epigenetic factors leads to alterations in normal colonic mucosa to develop into invasive cancer (**Vatandoo N, Ghanbari J et al., 2016**). The major etiological and risk factors for CRC have been identified. Genetic and environmental alterations interact in a complex way (**Bahrami A, Hassanian SM et al., 2017; Bahrami A, Hesari A, et al., 2017**). The overall heritability of CRC has been estimated to be 20–30%, and while important for familial CRC, the genetic factors have not been clarified (**Vatandoost N, Ghanbari J et al., 2016**).

1.2. Causes/Risk Factors of GIT Cancer:

The exact cause of GIT cancer is unknown; however, researchers have learned that there are certain risk factors associated with the development of GIT cancer. These factors differ according to the type of GIT cancers and include:

1.2.1 Lifestyle Factors:

The Incidence of GIT cancer correlates greatly with certain lifestyle factors, including: Diet, Alcohol consumption and smoking.

- **Diet** an increase of fiber, raw fruit and vegetable consumption is associated with a significant decrease of GIT cancer including; gastric, Pancreatic and colorectal cancer risk. Consumption of nitrates, refined carbohydrates (white